CWIR board/director David Platt OXYGEN THERAPY board members.....stunning LEGIT.... http://www.otipharma.com/wp-content/uploads/2017/03/OT-short-presentation-03-16-2017-V-2.0.pdf David Platt, Ph.D. CEO/Chairman of the Board Dr. Platt is a world-renowned expert in carbohydrate chemistry and has founded three publiclytraded companies, creating nearly $1B for investors. Prior to Boston Therapeutics, (OTC: BTHE) from 2001 to 2009, Dr. Platt was a founder, Chief Executive Officer and Chairman of the Board at ProPharmaceuticals, Inc. (OTC:PRWP and AMEX: PRW, NASDAQ: GALT). From 1995 to 2000 Dr. Platt was the founder of International Gene Group (NASDAQ: IGGI, GLGS)
Yuval Kwintner B.S., MBA, LL.B President & Board Member An experienced entrepreneur and business executive with proven abilities in both established organizations and start-up ventures. Earned an MBA from MIT Sloan School of Management, a B.Sc. from the Technion - Israel Institute of Technology, and an LL.B. (JD equivalent) from Tel Aviv University
Dr. Ben-Zion Weiner, PhD SCIENTIFIC ADVISORY BOARD CHAIRMAN Dr. Ben-Zion Weiner was Head of Global Research and Development at Teva Pharmaceutical Industries Ltd. for over three decades, including as a member of the Teva Executive Committee. He directly oversaw all pharmaceutical development and regulatory approval of Teva’s innovative product pipeline. Dr. Weiner was also responsible for the development of hundreds of generic products for the US, European, and other markets. He received a BSc degree in general chemistry and biochemistry and an MSc degree in organic chemistry, graduating with distinction for both degrees from the Hebrew University, Jerusalem. He received his PhD degree in chemistry at the Hebrew University, Jerusalem, and conducted his post-doctoral research at Schering-Plough Corporation in the United States.
Hana Chen-Walden, M.D. Medical Advisory Board Chairman Dr. Chen-Walden is an Endocrinologist and has specialized in regulatory affairs in the pharmaceutical industry in the U.S and Europe. Dr. Chen-Walden has more than 35 years of regulatory experience with the EMEA and in individual European Dr. Chen Walden received her Doctorate of Medicine from University of Tel Aviv, Israel. Dr. Chen-Walden has practiced medicine in Germany and France
Benjamin Rivnay, Ph.D. Chief Scientist Director of R&D at Formatech Managed 50+ projects on formulation development Vice President, R&D and Lab Director at Repromedix: Introduced over 50 new test products Senior Investigator and Program Leader at Procept: Initiated and led R&D programs Senior Scientist at Neurex Corporation Associate Professor of Biochemistry Ph.D., Biochemistry, Weizmann Institute of Science; B.Sc., Biology, Tel Aviv University
Ache Stokelman, B.S. Senior Advisor Ache is a veteran of the Biotech industry. He spent over 20 years at Amgen where he invented, developed and deployed new technologies and methods for Process Development. Earlier in his career he designed, build and troubleshoot safety and control systems on offshore platforms. He obtained a BS in Mechanical Engineering at The Technion Institute of Technology, Israel